Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey

被引:132
作者
Imbert, C [1 ]
Bezard, E [1 ]
Guitraud, S [1 ]
Boraud, T [1 ]
Gross, CE [1 ]
机构
[1] Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France
关键词
clinical rating scales; experimental Parkinsonism; MPTP; L-DOPA; clinical trial;
D O I
10.1016/S0165-0270(99)00184-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The most valuable model of Parkinson's disease available at present is the primate model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), frequently used to study response to new drugs or surgical treatments. The evaluation of such therapies requires clinical rating scales which measure precisely motor behaviour in both normal and parkinsonian monkeys. It is obvious that such evaluation can only be valid if parallel studies are carried out under similar experimental conditions with well-defined objective criteria. Hence the need to compare and assess the different rating scales in use if we want to be able to compare the results of clinical studies. In order to give rise to some fresh thinking on the necessity of a certain uniformity of assessment, this study compares eight clinical rating scales and considers their capacity to express in quantitative terms both the severity of MPTP intoxication in five cynomolgus monkeys and the alleviation afforded by levodopa. None of the eight scales reaches all the criteria despite the Kurlan scale would appear as an interesting working basis for a further consensual definition of a worldwide used parkinsonian monkey clinical rating scale (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 41 条
[1]  
BANKIEWICZ KS, 1988, PROG BRAIN RES, V78, P543
[2]  
Bédard PJ, 1999, MOVEMENT DISORD, V14, P4
[3]  
BEDARD PJ, 1992, NEUROMETHODS, V21, P159
[4]   RILUZOLE PREVENTS MPTP-INDUCED PARKINSONISM IN THE RHESUS-MONKEY - A PILOT-STUDY [J].
BENAZZOUZ, A ;
BORAUD, T ;
DUBEDAT, P ;
BOIREAU, A ;
STUTZMANN, JM ;
GROSS, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 284 (03) :299-307
[5]   REVERSAL OF RIGIDITY AND IMPROVEMENT IN MOTOR-PERFORMANCE BY SUBTHALAMIC HIGH-FREQUENCY STIMULATION IN MPTP-TREATED MONKEYS [J].
BENAZZOUZ, A ;
GROSS, C ;
FEGER, J ;
BORAUD, T ;
BIOULAC, B .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1993, 5 (04) :382-389
[6]  
BENAZZOUZ A, 1992, EXP BRAIN RES, V90, P116
[7]   REVERSAL OF EXPERIMENTAL PARKINSONISM BY LESIONS OF THE SUBTHALAMIC NUCLEUS [J].
BERGMAN, H ;
WICHMANN, T ;
DELONG, MR .
SCIENCE, 1990, 249 (4975) :1436-1438
[8]   Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model [J].
Bezard, E ;
Stutzmann, JM ;
Imbert, C ;
Boraud, T ;
Boireau, A ;
Gross, CE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (2-3) :101-104
[9]   Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms [J].
Bézard, E ;
Boraud, T ;
Bioulac, B ;
Gross, CE .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (06) :2167-2170
[10]   Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental Parkinsonism [J].
Bezard, E ;
Boraud, T ;
Bioulac, B ;
Gross, CE .
NEUROSCIENCE, 1997, 81 (02) :399-404